{"id":64010,"date":"2026-03-12T19:29:03","date_gmt":"2026-03-12T13:59:03","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/"},"modified":"2026-03-20T08:58:35","modified_gmt":"2026-03-20T03:28:35","slug":"stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi","status":"publish","type":"post","link":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/","title":{"rendered":"Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/api.newsfilecorp.com\/newsinfo\/288256\/511\" width=\"2\" height=\"2\"><\/p>\n<p>Dallas, Texas&#8211;(Newsfile Corp. &#8211; March 12, 2026) &#8211; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc      Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The Company&#8217;s lead program,      NEO212, is a next-generation version of temozolomide (TMZ), the standard-of-care chemotherapy used in most brain cancer patients. It is designed to address key limitations of current treatment      including BBB penetration and MGMT-driven resistance. Its platform includes NEO100 and NEO212, discussed in further detail below. Beyond its lead programs, NeOnc&#8217;s platform approach combines      intranasal and oral drug delivery technologies designed to improve CNS drug penetration, supporting additional opportunities across multiple brain tumor indications. Lastly, NTHI recently led a      successful PIPE offering, adding a gross $16.0M to the Company&#8217;s balance sheet.    <\/p>\n<p>      To view the full announcement, including downloadable images, bios, and more, <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/EZNAPUj2Rn\">click here<\/a>.    <\/p>\n<p>      <b>Key Takeaways:<\/b>    <\/p>\n<ul>\n<li>NEO212 (oral chemotherapy): A next-generation version of temozolomide designed to improve blood-brain barrier penetration and overcome MGMT-driven resistance in glioblastoma (GBM),      targeting a large population where standard TMZ therapy frequently fails.      <\/li>\n<li>NEO212 clinical momentum: Phase 1 dose escalation in recurrent GBM has completed with a Recommended Phase 2 Dose of 610 mg established and early signs of disease control observed,      positioning the program to advance into Phase 2 efficacy evaluation.      <\/li>\n<li>NEO100 (intranasal therapy): A non-invasive drug delivery approach targeting recurrent GBM, with Phase 2 data showing radiographic responses and improved progression-free survival versus      historical salvage benchmarks.      <\/li>\n<\/ul>\n<p>      <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/xExGBcKarb\"><img decoding=\"async\" src=\"https:\/\/images.newsfilecorp.com\/files\/7294\/288256_figure1.png\" alt=\"Cannot view this image? Visit: https:\/\/images.newsfilecorp.com\/files\/7294\/288256_figure1.png\"><\/a>    <\/p>\n<p>      <i>Click image above to view full announcement.<\/i>    <\/p>\n<hr>\n<p>      <strong>About Stonegate<br \/><\/strong>Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach      services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.    <\/p>\n<div>\n<p>      <b>Contacts:<\/b>    <\/p>\n<p>      Stonegate Capital Partners<br \/>      (214) 987-4121<br \/>      <a href=\"mailto:info@stonegateinc.com\">info@stonegateinc.com<\/a>    <\/p>\n<p>      Source: <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/7noYzuMeWv\">Stonegate, Inc.<\/a><\/p>\n<\/div>\n<p>      To view the source version of this press release, please visit <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/eje3xuMzBO\">https:\/\/www.newsfilecorp.com\/release\/288256<\/a>    <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dallas, Texas&#8211;(Newsfile Corp. &#8211; March 12, 2026) &#8211; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The Company&#8217;s lead program, NEO212, &hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32016],"tags":[],"class_list":["post-64010","post","type-post","status-publish","format-standard","","category-press-releases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) - Matribhumi Samachar English<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) - Matribhumi Samachar English\" \/>\n<meta property=\"og:description\" content=\"Dallas, Texas&#8211;(Newsfile Corp. &#8211; March 12, 2026) &#8211; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The Company&#8217;s lead program, NEO212, &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/\" \/>\n<meta property=\"og:site_name\" content=\"Matribhumi Samachar English\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-12T13:59:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T03:28:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/api.newsfilecorp.com\/newsinfo\/288256\/511\" \/>\n<meta name=\"author\" content=\"Saransh Kanaujia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saransh Kanaujia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/\",\"name\":\"Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) - Matribhumi Samachar English\",\"isPartOf\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\"},\"datePublished\":\"2026-03-12T13:59:03+00:00\",\"dateModified\":\"2026-03-20T03:28:35+00:00\",\"author\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\"},\"breadcrumb\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/matribhumisamachar.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/\",\"name\":\"Matribhumi Samachar English\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\",\"name\":\"Saransh Kanaujia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"caption\":\"Saransh Kanaujia\"},\"description\":\"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.\",\"sameAs\":[\"https:\/\/matribhumisamachar.com\/en\"],\"url\":\"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) - Matribhumi Samachar English","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/","og_locale":"en_US","og_type":"article","og_title":"Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) - Matribhumi Samachar English","og_description":"Dallas, Texas&#8211;(Newsfile Corp. &#8211; March 12, 2026) &#8211; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The Company&#8217;s lead program, NEO212, &hellip;","og_url":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/","og_site_name":"Matribhumi Samachar English","article_published_time":"2026-03-12T13:59:03+00:00","article_modified_time":"2026-03-20T03:28:35+00:00","og_image":[{"url":"https:\/\/api.newsfilecorp.com\/newsinfo\/288256\/511"}],"author":"Saransh Kanaujia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Saransh Kanaujia","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/","url":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/","name":"Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) - Matribhumi Samachar English","isPartOf":{"@id":"https:\/\/matribhumisamachar.com\/en\/#website"},"datePublished":"2026-03-12T13:59:03+00:00","dateModified":"2026-03-20T03:28:35+00:00","author":{"@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1"},"breadcrumb":{"@id":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/matribhumisamachar.com\/en\/"},{"@type":"ListItem","position":2,"name":"Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)"}]},{"@type":"WebSite","@id":"https:\/\/matribhumisamachar.com\/en\/#website","url":"https:\/\/matribhumisamachar.com\/en\/","name":"Matribhumi Samachar English","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1","name":"Saransh Kanaujia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","caption":"Saransh Kanaujia"},"description":"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.","sameAs":["https:\/\/matribhumisamachar.com\/en"],"url":"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/"}]}},"_links":{"self":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/64010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=64010"}],"version-history":[{"count":1,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/64010\/revisions"}],"predecessor-version":[{"id":65108,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/64010\/revisions\/65108"}],"wp:attachment":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=64010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=64010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=64010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}